<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BC911109-1671-4D57-BF27-8F8A86FF2D10"><gtr:id>BC911109-1671-4D57-BF27-8F8A86FF2D10</gtr:id><gtr:name>HUMABs Biomed, Bellinzona,Switzerland</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2B34C56C-8256-4C5C-8573-F768E7643896"><gtr:id>2B34C56C-8256-4C5C-8573-F768E7643896</gtr:id><gtr:name>Institute of Health Carlos III</gtr:name><gtr:address><gtr:line1>Instituto de Salud Carlos III</gtr:line1><gtr:line2>c/Sinesio delgado 3, Pabellon 3</gtr:line2><gtr:postCode>E28029</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BC911109-1671-4D57-BF27-8F8A86FF2D10"><gtr:id>BC911109-1671-4D57-BF27-8F8A86FF2D10</gtr:id><gtr:name>HUMABs Biomed, Bellinzona,Switzerland</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2B34C56C-8256-4C5C-8573-F768E7643896"><gtr:id>2B34C56C-8256-4C5C-8573-F768E7643896</gtr:id><gtr:name>Institute of Health Carlos III</gtr:name><gtr:address><gtr:line1>Instituto de Salud Carlos III</gtr:line1><gtr:line2>c/Sinesio delgado 3, Pabellon 3</gtr:line2><gtr:postCode>E28029</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5DC8742C-F283-44E9-9393-25DE98BDE551"><gtr:id>5DC8742C-F283-44E9-9393-25DE98BDE551</gtr:id><gtr:firstName>Geraldine</gtr:firstName><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FI%2F00001709"><gtr:id>47347208-0613-4F65-8C46-E9C9EC888C1D</gtr:id><gtr:title>Host resistance mechanisms to bovine respiratory syncytial virus (BRSV), African swine fever virus (ASFV) and Bluetongue virus (BTV)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/I/00001709</gtr:grantReference><gtr:abstractText>The aim of this project is to advance understanding of the mechanisms of immunity to and the pathogenesis of African swine fever virus (ASFV), bluetongue virus (BTV) and bovine respiratory syncytial virus (BRSV). The knowledge gained will contribute to the development of new or improved vaccines. Developments in DNA technology have created new opportunities for vaccine production, both through genetic manipulation of pathogens and by enabling the identification of defined antigens that induce protective immune responses. These opportunities, together with a detailed understanding of the components of the immune response that mediate protection or which contribute to the pathogenesis of disease, and knowledge of how these responses can be induced and regulated at an appropriate location in vivo, will provide a conceptual framework for the rational development of new or improved vaccines against BRSV, ASFV and BTV.</gtr:abstractText><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>3222491</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>HUMABs Biomed, Bellinzona,Switzerland</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>BRSV prefusion F</gtr:description><gtr:id>87407431-8D03-4477-B277-949904B7CC1B</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56deb8ae7ec849.93224731-2</gtr:outcomeId><gtr:partnerContribution>Production of purified BRSV F proteins</gtr:partnerContribution><gtr:piContribution>Evaluation of the immunogenicity and protective efficacy of different forms of the bovine respiratory syncytial virus F protein in calves.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Health Carlos III</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Prefusion HRSV F</gtr:description><gtr:id>254D9806-C770-4F12-A875-C3577133E44A</gtr:id><gtr:impact>A manuscript has been published</gtr:impact><gtr:outcomeId>56deb588629e91.92320167-1</gtr:outcomeId><gtr:partnerContribution>Provision of purified proteins for vaccination &amp;amp; analysis of serum antibody responses</gtr:partnerContribution><gtr:piContribution>Evaluation of the immunogenicity and protective efficacy of the different forms of the human respiratory syncytial virus F protein in mice.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Vaccine Research Center (VRC)</gtr:department><gtr:description>BRSV prefusion F</gtr:description><gtr:id>BB1D867B-EB11-4F74-9231-5E96DB1E8DF0</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56deb8ae7ec849.93224731-1</gtr:outcomeId><gtr:partnerContribution>Production of purified BRSV F proteins</gtr:partnerContribution><gtr:piContribution>Evaluation of the immunogenicity and protective efficacy of different forms of the bovine respiratory syncytial virus F protein in calves.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Vaccinology in Africa course</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BA1E1AEA-367B-43DD-BDDB-1D71B5343C68</gtr:id><gtr:impact>30 scientists from Africa working in the Vaccinology field attended. The presentations and workshops sparked questions and a lot of discussion.

There were requests to repeat the course in other regions in Africa</gtr:impact><gtr:outcomeId>stN8qSaGMv1</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Advances for an RSV vaccine</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CC60F98C-5ED2-4EB0-907F-32D5482B6A40</gtr:id><gtr:impact>Interview with a reporter from a Surrey radio station about recent advances in the development of a vaccine to protect against RSV in babies following publication of a paper (http://stm.sciencemag.org/content/7/300/300ra127.short), which was broadcast the next day.</gtr:impact><gtr:outcomeId>56deda8268b328.42846435</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://stm.sciencemag.org/content/7/300/300ra127.short</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Human &amp; Veterinary Vaccinology course</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F79CFEA1-0D5F-493D-8E80-9C5484870819</gtr:id><gtr:impact>30 people (post-graduate students, scientsits from academia and industry) attended. Presentations and workshops sparked questions and discussion.

Not known</gtr:impact><gtr:outcomeId>a6PfJpxsxiE</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>https://www.conted.ox.ac.uk/courses/C900-1</gtr:url><gtr:year>2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Babraham Institute Ethics event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1F210A22-D58A-496F-B4C6-556E0DA5F3EC</gtr:id><gtr:impact>Approximately 50 school children attended the event at the Babraham institute to learn about the use of animals in research and the three Rs - Refinement, Reduction and Replacement - which govern such use. They heard about breakthroughs in medicine and healthcare treatments that have only been possible through doing research with animals, about the work of The Pirbright Institute in the development of vaccines and control strategies to prevent viral diseases in livestock and transmission of viruses from animals to humans, and about research that is currently being carried out by the Babraham Institute into Alzheimer's disease. The workshop broadened the pupils' knowledge of biomedical research and its applications and encouraged them to think about the wider social and ethical implications of scientific discoveries they hear about in the news and other media.</gtr:impact><gtr:outcomeId>56ded81773f315.22838981</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://babraham.ac.uk/get-involved/secondary-schools/ethics-workshops</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Grand Challenges Explorations</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:fundingRef>OPP1098823</gtr:fundingRef><gtr:id>32249E99-4291-4D7F-8EB3-0757A1281820</gtr:id><gtr:outcomeId>56debb9e18eb95.34368221</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>239067</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Horizon 2020</gtr:description><gtr:end>2019-02-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>633184</gtr:fundingRef><gtr:id>A48877BB-BF95-4104-A87B-1EEFFAFFF484</gtr:id><gtr:outcomeId>56dec75eb72275.82206227</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>African swine fever is a devastating disease of pigs which has spread to the borders of the EU in recent years. We have identified antigens that are recognised by ASFV immune lymphocytes and these have been expressed in replication defective adenovirus vectors and will be evaluated as potential vaccine candidates. A patent application for ths novel ASFV vaccine is being prepared.
An Adenovirus-vectored vaccine expressing the surface glycoproteins of peste des petits ruminants virus (PPRV) has been developed and was shown to induce complete protection against PPR challenge, 3 months after a single intramuscular dose of vaccine. This vaccine has the potential to distinguish vaccinated from infected animals and would be of value in the end stages of a PPR eradication campaign.
An adenovirus-vectored and MVA-vectored RSV vaccine for use in man against human RSV has been developed and was shown to be effective against the closely related BRSV in calves. this vaccine is now in clinical trials in man.
A prefusion form of the BRSV F protein has ben shown to elicit higher tires of neutralising antibodies and greater protection against BRSV infection than the post-fusion BRSV</gtr:description><gtr:firstYearOfImpact>2016</gtr:firstYearOfImpact><gtr:id>AFB3FC89-3755-4F26-B402-2B2BE5A6CEE7</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>545ce77c7bd140.50616904</gtr:outcomeId><gtr:sector>Agriculture, Food and Drink,Healthcare</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>In humans and mice, ?d T cells represent approximately 5% of the total circulating lymphocytes. In contrast, the ?d T cell compartment in ruminants accounts for 15-60% of the total circulating mononuclear lymphocytes. Despite the existence of CD4(+)CD25(high) Foxp3(+) T cells in the bovine system, these are neither anergic nor suppressive. We have demonstrated that bovine ?d T cells are the major regulatory T cell subset in peripheral blood. These ?d T cells spontaneously secrete IL-10 and proliferate in response to IL-10, TGF-?, and contact with antigen-presenting cells (APC). IL-10-expressing ?d T cells inhibit antigen-specific and nonspecific proliferation of CD4(+) and CD8(+) T cells in vitro. APC subsets expressing IL-10 and TFG-? regulate proliferation of ?d T cells producing IL-10. ?d T cells appear to be a major regulatory T cell population in the bovine system.

Bovine respiratory syncytial virus (BRSV) causes inflammation and obstruction of the small airways, leading to severe respiratory disease in young calves. The virus is closely related to human (H)RSV, a major cause of bronchiolitis and pneumonia in young children. The ability to manipulate the genome of RSV has provided opportunities for the development of stable, live attenuated RSV vaccines. The role of the SH protein in the pathogenesis of BRSV was evaluated in vitro and in vivo using a recombinant (r)BRSV in which the SH gene had been deleted. Infection of bovine epithelial cells and monocytes with rBRSV?SH, in vitro, resulted in an increase in apoptosis, and higher levels of pro-inflammatory cytokines compared with cells infected with parental, wild-type (WT) rBRSV. Although replication of rBRSV?SH and WT rBRSV, in vitro, were similar, the replication of rBRSV?SH was moderately reduced in the lower, but not the upper, respiratory tract of experimentally infected calves. Despite the greater ability of rBRSV?SH to induce pro-inflammatory cytokines, in vitro, the pulmonary inflammatory response in rBRSV?SH-infected calves was significantly reduced compared with that in calves inoculated with WT rBRSV, 6 days previously. Virus lacking SH appeared to be as immunogenic and effective in inducing resistance to virulent virus challenge, 6 months later, as the parental rBRSV. Furthermore, intranasal vaccination of calves with maternally-derived antibodies induced protection against viruelnt virus challenge.These findings suggest that rBRSV?SH may be an ideal live attenuated virus vaccine candidate, combining safety with a high level of immunogenicity.

The immunogenicity and protective efficacy of a virus-vectored human RSV vaccine was evaluated against BRSV in calves and a heterologous prime/boost regimen was shown to give sterile immunity against BRSV.

Bovine plasmacytoid dendritic cells produce high levels of IFN, some of which is acid labile, when exposed to live, but not UV-inactivated, BTV. The response is enhanced when BTV is complexed with BTV-specific antibodies. Different serotypes of BTV differ in their ability to induce IFN

In contrast to the well-described, CAR-dependent mechanism of adenovirus attachment and penetration of permissive cells, we demonstrated that adenovirus enters skin-draining dendritic cells via actin-dependent endocytosis

African swine fever virus (ASFV) inhibits autophagy at early times post infection. This has implications for induction of adaptive immune responses. ASFV ORFs recognised by ASFV-immune lymphocytes from cc, dd and bb pigs have been identified and cloned into replication-defective adenovirus vectors for development of ASFV vaccine candidates. Vaccination of a small number of pigs with a pool of adenovirus-vectored vaccines induced protection against severe disease and reduced viraemia in 50% of the pigs. A number of tagged ASF viruses have been generated that encode a fluorescent-virus structural fusion protein in the place of a non-essential gene. These will be of value in studying the pathogensis of ASFV in pigs and ticks.
A prefusion form of the BRSV F protein induces higher levels of neutralising antibodies and a greater level of protection against BRSV infection than the post0fusion form of the F protein</gtr:description><gtr:exploitationPathways>A grant has been submitted to further develop rBRSVdelta SH as a vaccine for calf respiratory disease. A PhD student will investigate the effect of ASFV on autophagy further. 
A grant has been submitted to extend studies on bovine gamma/delta T cells and determine their role in combatting virus infection.
A Bill &amp;amp; Melinda Gates grant was awarded to determine the minimum protective dose of the Ad-vectored PPR vaccine in African goats.
Clinical trials of the virus-vectored RSV vaccine have been undertaken in man.
The prefusion form of the BRSV F protein could be developed as a vaccine</gtr:exploitationPathways><gtr:id>1A9838F7-23C3-4AA7-8263-58D6A27A0E64</gtr:id><gtr:outcomeId>545cecfbf236b0.96670123</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Pre-clinical studies have demonstrated efficacy in small animal models of RSV infection and against bovine RSV infection in calves, a natural host of BRSV. These studies demonstrated that the vaccine was safe and effective in calves without any enhancement of respiratory disease. As a result of this, the vaccine has now undergone phase I clinical trials in Oxford, funded by Okairos and GSK and was shown to be safe and immunogenic (http://bmjopen.bmj.com/content/5/10/e008748.full).</gtr:description><gtr:id>CCCC38C7-6E46-4894-B50E-4355628DCDF9</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545cf9ee420613.42265545</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>RSV vaccine</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:ukcrnIsctnId>35082/0003/001-0001</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AA1B4263-77FB-4B48-9942-308230A051E1</gtr:id><gtr:title>Evidence for transmission of bluetongue virus serotype 26 through direct contact.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf928ae837d8b0796e54ff406bfcbda6"><gtr:id>bf928ae837d8b0796e54ff406bfcbda6</gtr:id><gtr:otherNames>Batten C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545cef962b32b9.60191911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>878B13EF-29ED-4A24-8F80-27762818638A</gtr:id><gtr:title>An infectious recombinant foot-and-mouth disease virus expressing a fluorescent marker protein.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b5ec0ebcc691662b7092a6145fd67ae"><gtr:id>5b5ec0ebcc691662b7092a6145fd67ae</gtr:id><gtr:otherNames>Seago J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>545caf3665c1c1.41371709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>107E4403-CEB6-4AEF-9A9C-3082B855024C</gtr:id><gtr:title>Deletion of virulence associated genes from attenuated African swine fever virus isolate OUR T88/3 decreases its ability to protect against challenge with virulent virus.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aadd27cdd611ca10860ceed444e5e1de"><gtr:id>aadd27cdd611ca10860ceed444e5e1de</gtr:id><gtr:otherNames>Abrams CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>545caf363d60c1.12699776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5B06807-93B7-4668-9378-86B9E80472CF</gtr:id><gtr:title>Encyclopedia of Cell Biology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1eb115a44cc87d30218cf02d50091e1"><gtr:id>a1eb115a44cc87d30218cf02d50091e1</gtr:id><gtr:otherNames>Wileman T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:isbn>9780123947963</gtr:isbn><gtr:outcomeId>566a9a138d59b5.38540233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D509119-70A6-4F2D-8542-2E682095CFBD</gtr:id><gtr:title>Characterization of an experimental vaccine for bovine respiratory syncytial virus.</gtr:title><gtr:parentPublicationTitle>Clinical and vaccine immunology : CVI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9abc01326cdb82ab08a5589d910985fb"><gtr:id>9abc01326cdb82ab08a5589d910985fb</gtr:id><gtr:otherNames>H?gglund S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1556-679X</gtr:issn><gtr:outcomeId>545cae78018160.21442574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDB28895-A721-4F09-8099-C44D83B4BD2F</gtr:id><gtr:title>Immunisation of pigs by DNA prime and recombinant vaccinia virus boost to identify and rank African swine fever virus immunogenic and protective proteins.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65abcf4c7c04255298e26cfeaffc0e00"><gtr:id>65abcf4c7c04255298e26cfeaffc0e00</gtr:id><gtr:otherNames>Jankovich JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5a993c04ede8c7.38723371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E008202-851D-4D27-A13A-867CADDCAAE7</gtr:id><gtr:title>Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Methods &amp; clinical development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/004395d8543892847b89f9480cfaa545"><gtr:id>004395d8543892847b89f9480cfaa545</gtr:id><gtr:otherNames>Pierantoni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2329-0501</gtr:issn><gtr:outcomeId>566a9a12b2b4c1.36917540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5F8252A-1EC1-46D8-AC3E-036D43DFFEE1</gtr:id><gtr:title>Determination of the minimum fully protective dose of adenovirus-based DIVA vaccine against peste des petits ruminants virus challenge in East African goats.</gtr:title><gtr:parentPublicationTitle>Veterinary research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7706231a740b7113c3949991408a565"><gtr:id>d7706231a740b7113c3949991408a565</gtr:id><gtr:otherNames>Holzer B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0928-4249</gtr:issn><gtr:outcomeId>56dea026ae3047.23658790</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69ADE784-0200-4CF4-AE50-19C648A376D1</gtr:id><gtr:title>Foot-and-mouth disease virus induces autophagosomes during cell entry via a class III phosphatidylinositol 3-kinase-independent pathway.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/153b42ccc56bf82861913f423b4060c5"><gtr:id>153b42ccc56bf82861913f423b4060c5</gtr:id><gtr:otherNames>Berryman S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5a993c04504747.10604227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC732B9C-8755-42FF-B09D-C6C9415161D5</gtr:id><gtr:title>Early changes in cytokine expression in peste des petits ruminants disease.</gtr:title><gtr:parentPublicationTitle>Veterinary research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbf0ce63e4fec801110e199ac2bc1dea"><gtr:id>bbf0ce63e4fec801110e199ac2bc1dea</gtr:id><gtr:otherNames>Baron J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0928-4249</gtr:issn><gtr:outcomeId>545caf357dcc95.32455132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FE5DD6E-0ADA-47E2-A6AE-3EA334CB0A30</gtr:id><gtr:title>Using shared needles for subcutaneous inoculation can transmit bluetongue virus mechanically between ruminant hosts.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62b3778af934147411913a5e8b8cabbc"><gtr:id>62b3778af934147411913a5e8b8cabbc</gtr:id><gtr:otherNames>Darpel KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56d03a35170972.46798992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>891B9509-D51D-4D96-B529-59506197A0F1</gtr:id><gtr:title>Prospects for development of African swine fever virus vaccines.</gtr:title><gtr:parentPublicationTitle>Developments in biologicals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d3259055c4cb11ecd6b24f5725fbede"><gtr:id>7d3259055c4cb11ecd6b24f5725fbede</gtr:id><gtr:otherNames>Dixon LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>978-3-318-02365-7</gtr:isbn><gtr:issn>1424-6074</gtr:issn><gtr:outcomeId>545caf35a482d3.70968829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6E191AF-2BE2-4B32-8E48-E8EC3B98E46A</gtr:id><gtr:title>Modulation of the transcription factor NF-?B in antigen-presenting cells by bovine respiratory syncytial virus small hydrophobic protein.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ba7dc83e4859610e4809c7d777b522b"><gtr:id>3ba7dc83e4859610e4809c7d777b522b</gtr:id><gtr:otherNames>Pollock N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>59720b74bf4170.71586958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05997617-6404-4761-9E96-51C272A08158</gtr:id><gtr:title>The double-stranded RNA bluetongue virus induces type I interferon in plasmacytoid dendritic cells via a MYD88-dependent TLR7/8-independent signaling pathway.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4631cec40764f5fcd4d4e56801935cb"><gtr:id>a4631cec40764f5fcd4d4e56801935cb</gtr:id><gtr:otherNames>Ruscanu S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>545cae2219c2a0.51428249</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC0F920E-9D82-40AC-AE7E-8E6A620208CF</gtr:id><gtr:title>Recombinant bovine respiratory syncytial virus with deletion of the SH gene induces increased apoptosis and pro-inflammatory cytokines in vitro, and is attenuated and induces protective immunity in calves.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb166f172d6376a3795a3a2d84a54351"><gtr:id>bb166f172d6376a3795a3a2d84a54351</gtr:id><gtr:otherNames>Taylor G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>545c9e1321fd41.50172706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41233C16-0B0A-47F9-B922-B59254A03ED1</gtr:id><gtr:title>Increase in chemokines CXCL10 and CCL2 in blood from pigs infected with high compared to low virulence African swine fever virus isolates.</gtr:title><gtr:parentPublicationTitle>Veterinary research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36bcfa78982ee340716b8da27b54b9c6"><gtr:id>36bcfa78982ee340716b8da27b54b9c6</gtr:id><gtr:otherNames>Fishbourne E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0928-4249</gtr:issn><gtr:outcomeId>566a9a13377b22.36827819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DD46AE5-D881-44FC-AE9F-54964DB76CBF</gtr:id><gtr:title>African swine fever virus organelle rearrangements.</gtr:title><gtr:parentPublicationTitle>Virus research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fff8213e2a45f73d17953f4929a5cb79"><gtr:id>fff8213e2a45f73d17953f4929a5cb79</gtr:id><gtr:otherNames>Netherton CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-1702</gtr:issn><gtr:outcomeId>5a993c041a5460.27064488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEE7900E-F1D8-4B43-A3BB-E869BE317C2A</gtr:id><gtr:title>Bovine model of respiratory syncytial virus infection.</gtr:title><gtr:parentPublicationTitle>Current topics in microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb166f172d6376a3795a3a2d84a54351"><gtr:id>bb166f172d6376a3795a3a2d84a54351</gtr:id><gtr:otherNames>Taylor G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>978-3-642-38918-4</gtr:isbn><gtr:issn>0070-217X</gtr:issn><gtr:outcomeId>545cae782bd522.37553829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E339D6A-24E0-4D65-A2F2-3270EDFA0FB8</gtr:id><gtr:title>Deletion of African swine fever virus interferon inhibitors from the genome of a virulent isolate reduces virulence in domestic pigs and induces a protective response.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e16a44ca574b321d3fbce50cf405e095"><gtr:id>e16a44ca574b321d3fbce50cf405e095</gtr:id><gtr:otherNames>Reis AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>58c90f77141614.65562815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B160D190-D988-4BE6-8BED-FE8CBB0DD2F5</gtr:id><gtr:title>Cellular immunity in ASFV responses.</gtr:title><gtr:parentPublicationTitle>Virus research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41b92c13d77a90322c1ec5c0332f04fc"><gtr:id>41b92c13d77a90322c1ec5c0332f04fc</gtr:id><gtr:otherNames>Takamatsu HH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-1702</gtr:issn><gtr:outcomeId>545ca8d033ba14.77475204</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACE758D7-E51B-4EAF-9295-C28613B473FC</gtr:id><gtr:title>Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3df7d9c06e28d0a0323b53f564b4a72e"><gtr:id>3df7d9c06e28d0a0323b53f564b4a72e</gtr:id><gtr:otherNames>Blod?rn K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545cae77ca79d0.87430639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE7AC823-A4E5-4D36-9E3F-2B1E0EAE92CD</gtr:id><gtr:title>Identification of residues within the African swine fever virus DP71L protein required for dephosphorylation of translation initiation factor eIF2a and inhibiting activation of pro-apoptotic CHOP.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/756ed54beae457cf7d6420cffc470dea"><gtr:id>756ed54beae457cf7d6420cffc470dea</gtr:id><gtr:otherNames>Barber C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>58c90f768ad0d5.19108794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED13953F-0D16-4A9E-AE9D-A7E90693D3E7</gtr:id><gtr:title>Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e8c9a69155a3aa4c73a4c37a2ea939f"><gtr:id>2e8c9a69155a3aa4c73a4c37a2ea939f</gtr:id><gtr:otherNames>Sastry M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a958b18f20ba3.15601614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB83A17C-0526-4EB0-86C2-D7E95CF324E8</gtr:id><gtr:title>Protection of calves by a prefusion-stabilized bovine RSV F vaccine.</gtr:title><gtr:parentPublicationTitle>NPJ vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37ad02443c8a13325ab1a72e307dd092"><gtr:id>37ad02443c8a13325ab1a72e307dd092</gtr:id><gtr:otherNames>Zhang B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2059-0105</gtr:issn><gtr:outcomeId>58c6af7fad0b80.59915997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89BEFDFA-4E9B-4067-A9FD-F1DB1090D0AB</gtr:id><gtr:title>Intranasal immunisation with recombinant adenovirus vaccines protects against a lethal challenge with pneumonia virus of mice.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83ce80e1269879c104b7b2085fcfcbc2"><gtr:id>83ce80e1269879c104b7b2085fcfcbc2</gtr:id><gtr:otherNames>Maunder HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>56dea02676c680.55469321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA7CD979-F671-427E-8F8D-AA449074399B</gtr:id><gtr:title>Recombinant adenovirus expressing the haemagglutinin of Peste des petits ruminants virus (PPRV) protects goats against challenge with pathogenic virus; a DIVA vaccine for PPR.</gtr:title><gtr:parentPublicationTitle>Veterinary research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1839f663eaebc5a0443b5ce69dd05a3a"><gtr:id>1839f663eaebc5a0443b5ce69dd05a3a</gtr:id><gtr:otherNames>Herbert R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0928-4249</gtr:issn><gtr:outcomeId>545caf35c8f286.01658092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8C42C1F-3AFE-4C65-A062-E0BEEF789DCC</gtr:id><gtr:title>Proteome analysis of bronchoalveolar lavage from calves infected with bovine respiratory syncytial virus-Insights in pathogenesis and perspectives for new treatments.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9abc01326cdb82ab08a5589d910985fb"><gtr:id>9abc01326cdb82ab08a5589d910985fb</gtr:id><gtr:otherNames>H?gglund S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a958a85c64ab3.60837160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0AE5D83-1B37-4CC5-B1CC-3C3EE5285FF8</gtr:id><gtr:title>A bovine respiratory syncytial virus model with high clinical expression in calves with specific passive immunity.</gtr:title><gtr:parentPublicationTitle>BMC veterinary research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3df7d9c06e28d0a0323b53f564b4a72e"><gtr:id>3df7d9c06e28d0a0323b53f564b4a72e</gtr:id><gtr:otherNames>Blod?rn K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1746-6148</gtr:issn><gtr:outcomeId>566a9a12daf6a5.21536771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4718BDB-C8FF-49AF-99FB-DDE434FCF7CD</gtr:id><gtr:title>Different routes and doses influence protection in pigs immunised with the naturally attenuated African swine fever virus isolate OURT88/3.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c598a0b67d2909cf4e2298949ee52df"><gtr:id>3c598a0b67d2909cf4e2298949ee52df</gtr:id><gtr:otherNames>S?nchez-Cord?n PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>58c6b18bb2c7f4.76049273</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0DD709B-F3B9-40E8-8305-259BD3D32896</gtr:id><gtr:title>African swine fever virus strain Georgia 2007/1 in Ornithodoros erraticus ticks.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cd0e5bb8b833cc454bbdf405c955ae2"><gtr:id>2cd0e5bb8b833cc454bbdf405c955ae2</gtr:id><gtr:otherNames>Diaz AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>545caf361abb92.13450646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9AD5E06-B7BC-4E08-A272-138CBFB895C5</gtr:id><gtr:title>The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1e863e501dee503acf8b635e2154529"><gtr:id>f1e863e501dee503acf8b635e2154529</gtr:id><gtr:otherNames>Dicks MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>58c911f6ac67b5.16214128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>652F9788-9642-4487-B974-10EC7E324AEA</gtr:id><gtr:title>A role for endoplasmic reticulum exit sites in foot-and-mouth disease virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/695f463f06d34ef3ed27ebc9029580d0"><gtr:id>695f463f06d34ef3ed27ebc9029580d0</gtr:id><gtr:otherNames>Midgley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>545cad95bb6dd6.64965075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E45F83E4-48EB-4C95-B264-88074305A340</gtr:id><gtr:title>Modulation of chemokine and chemokine receptor expression following infection of porcine macrophages with African swine fever virus.</gtr:title><gtr:parentPublicationTitle>Veterinary microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36bcfa78982ee340716b8da27b54b9c6"><gtr:id>36bcfa78982ee340716b8da27b54b9c6</gtr:id><gtr:otherNames>Fishbourne E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0378-1135</gtr:issn><gtr:outcomeId>566a9a13639f45.21902454</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CB32498-A088-4F42-BC3F-7D09C160DC4F</gtr:id><gtr:title>Animal models of respiratory syncytial virus infection.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb166f172d6376a3795a3a2d84a54351"><gtr:id>bb166f172d6376a3795a3a2d84a54351</gtr:id><gtr:otherNames>Taylor G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5857fb8b8cb303.68745685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C10D5429-ACB5-4307-9807-D0DB907E3BC9</gtr:id><gtr:title>Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9570e671d3235446ee15370c99966263"><gtr:id>9570e671d3235446ee15370c99966263</gtr:id><gtr:otherNames>Palomo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>57f4f62e6deed2.67566226</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53DAF273-A29B-490A-AAD4-520073FF886B</gtr:id><gtr:title>Transduction of skin-migrating dendritic cells by human adenovirus 5 occurs via an actin-dependent phagocytic pathway.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d27c935f2e7d91d15756bc9a5ff238b0"><gtr:id>d27c935f2e7d91d15756bc9a5ff238b0</gtr:id><gtr:otherNames>Guzman E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>58c6b139824384.75321280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8D73B9A-44EA-4ACC-B4EA-06DBEA0573B0</gtr:id><gtr:title>Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb166f172d6376a3795a3a2d84a54351"><gtr:id>bb166f172d6376a3795a3a2d84a54351</gtr:id><gtr:otherNames>Taylor G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5675ea26c742f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1C854E1-1012-4FD4-8CE0-52BB950E0F07</gtr:id><gtr:title>Hyaluronidase Activity in Saliva of European Culicoides (Diptera: Ceratopogonidae).</gtr:title><gtr:parentPublicationTitle>Journal of medical entomology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5c4bdc840fe16f116688b2a187ce487"><gtr:id>e5c4bdc840fe16f116688b2a187ce487</gtr:id><gtr:otherNames>R?drov? J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2585</gtr:issn><gtr:outcomeId>56d038b9c44d28.89025763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31C41A5E-F45A-44DF-A874-AFA4CD7D6965</gtr:id><gtr:title>Bovine &amp;Icirc;&amp;sup3;&amp;Icirc;&amp;acute; T cells are a major regulatory T cell subset.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d27c935f2e7d91d15756bc9a5ff238b0"><gtr:id>d27c935f2e7d91d15756bc9a5ff238b0</gtr:id><gtr:otherNames>Guzman E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>545ca77b459617.86899081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>962BEF01-D2A3-42C2-ABFC-749C12D43329</gtr:id><gtr:title>Unraveling the Armor of a Killer: Evasion of Host Defenses by African Swine Fever Virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e16a44ca574b321d3fbce50cf405e095"><gtr:id>e16a44ca574b321d3fbce50cf405e095</gtr:id><gtr:otherNames>Reis AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>58c90f76e01c22.56010232</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8268036-14DC-4CA0-AA0C-D1BFE3986A11</gtr:id><gtr:title>African swine fever virus replication and genomics.</gtr:title><gtr:parentPublicationTitle>Virus research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d3259055c4cb11ecd6b24f5725fbede"><gtr:id>7d3259055c4cb11ecd6b24f5725fbede</gtr:id><gtr:otherNames>Dixon LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-1702</gtr:issn><gtr:outcomeId>545caf368dc230.73911595</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EED0C12-8A18-44B7-B8E1-B481816777FC</gtr:id><gtr:title>Sensitivity of African swine fever virus to type I interferon is linked to genes within multigene families 360 and 505.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14d3365a86157e6d3f17a734d849fd55"><gtr:id>14d3365a86157e6d3f17a734d849fd55</gtr:id><gtr:otherNames>Golding JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>57023abbca2458.93342808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>517EBD25-EDCB-4482-93AF-DC73183550CE</gtr:id><gtr:title>Survival of African Swine Fever Virus in Excretions from Pigs Experimentally Infected with the Georgia 2007/1 Isolate.</gtr:title><gtr:parentPublicationTitle>Transboundary and emerging diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8833ead6bf24af6f42ea2ae0ea4cf9f"><gtr:id>f8833ead6bf24af6f42ea2ae0ea4cf9f</gtr:id><gtr:otherNames>Davies K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1865-1674</gtr:issn><gtr:outcomeId>58c90f77419099.33415536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F236DAA-4025-4A11-9EC0-D0CCA69D9DCD</gtr:id><gtr:title>Immunology of bovine respiratory syncytial virus in calves.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d27c935f2e7d91d15756bc9a5ff238b0"><gtr:id>d27c935f2e7d91d15756bc9a5ff238b0</gtr:id><gtr:otherNames>Guzman E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>566a9a128c5bc5.11519744</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/I/00001709</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>